ADR Biomedical Holdings Inc.
Research ADR Biomedical Holdings Inc. (3750.T) on Bullrun: market cap JPY 6.80B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker3750.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyJPY
- Market capJPY 6.80B
- Financial periodFY2026
- RevenueJPY 50.99M
- Revenue growth-58.3%
- Net income-JPY 396.90M
- Free cash flow-JPY 784.77M
- Gross margin20.7%
Valuation Snapshot
latest market cap is JPY 6.80B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | JPY 50.99M | -JPY 396.90M | -JPY 784.77M | 20.7% | -44.46 | JPY 125.90M | JPY 0 | JPY 22.03M |
| FY2025 | JPY 122.20M | -JPY 2.14B | -JPY 995.12M | -4.9% | -239.7 | JPY 255.98M | JPY 2.65B | JPY 630.54M |
| FY2024 | JPY 1.56B | JPY 138.16M | -JPY 1.17B | 82.8% | 15.42 | JPY 1.04B | JPY 2.47B | JPY 2.79B |
| FY2023 | JPY 2.14B | -JPY 1.06B | -JPY 198.04M | 59.2% | -118.71 | JPY 1.12B | JPY 8.51B | JPY 2.65B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 6.80B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 JPY.
About ADR Biomedical Holdings Inc.
ADR Biomedical Holdings Inc. engages in the research, development, production, and sale of cell therapy related medical devices in Japan. The company sells cell therapy kits, as well as engages in the research and development of cell therapy technology, etc. Its products pipeline includes ECCI-50 for the treatment of male stress urinary incontinence; ECCL-50 to treat liver cirrhosis; and Cyt-006 to prevent postoperative adhesion for primary rectal cancer.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is ADR Biomedical Holdings Inc.'s market cap?
ADR Biomedical Holdings Inc.'s market capitalization is JPY 6.80B.
What does ADR Biomedical Holdings Inc. do?
ADR Biomedical Holdings Inc. engages in the research, development, production, and sale of cell therapy related medical devices in Japan. The company sells cell therapy kits, as well as engages in the research and development of cell therapy technology, etc. Its products pipeline includes ECCI-50 for the treatment of male stress urinary incontinence; ECCL-50 to treat liver cirrhosis; and Cyt-006 to prevent postoperative adhesion for primary rectal cancer.